A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- GSK Investigational Site
-
-
-
-
-
Panama City, Panama
- GSK Investigational Site
-
Punta Pacifica Panama City Panama, Panama
- GSK Investigational Site
-
-
-
-
California
-
San Francisco, California, United States, 94158
- GSK Investigational Site
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- GSK Investigational Site
-
Houston, Texas, United States, 77030
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- More than or equal to (≥)18 years of age
- Eastern cooperative oncology group (ECOG) class 0-2
- Life expectancy of a minimum of 3 month
- Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options (Part 1).
- Participant has metastatic, gBRCAmut, HER2-negative or HER2-low breast cancer who has completed at most 3 or more prior lines of therapy (Part 2).
Exclusion Criteria:
- Participant has not recovered (i.e., to Grade less than or equal to [≤1] or to baseline) from prior chemotherapy-induced AEs.
- Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.
- Participant has symptomatic uncontrolled brain or leptomeningeal metastases.
- Participant has a known additional malignancy that progressed or required active treatment within the last 2 years
- Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).
- Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) >140 millimetres of mercury (mmHg) or diastolic BP >90 mmHg.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1 - GSK4524101 Monotherapy
|
GSK452101 will be administered.
|
|
Experimental: Part 1 - GSK4524101 plus Niraparib
|
Niraparib will be administered.
GSK452101 will be administered.
|
|
Experimental: Part 1 - GSK4524101 Food Effect Cohort
|
GSK452101 will be administered.
|
|
Experimental: Part 2 - GSK4524101 plus Niraparib
|
Niraparib will be administered.
GSK452101 will be administered.
|
|
Active Comparator: Part 2 - Niraparib
|
Niraparib will be administered.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation Period
Time Frame: Up to 28 days
|
Up to 28 days
|
|
|
Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation Period
Time Frame: Up to 28 days
|
Up to 28 days
|
|
|
Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation Period
Time Frame: Up to 28 days
|
Up to 28 days
|
|
|
Part 2 - Confirmed Objective Response Rate (ORR)
Time Frame: Up to approximately 52 weeks
|
ORR is the percentage of participants with an Investigator-assessed confirmed complete response and confirmed partial response to treatment, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
|
Up to approximately 52 weeks
|
|
Part 1 - Proportion of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation Period
Time Frame: Up to 28 days
|
Up to 28 days
|
|
|
Part 1 - Proportion of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation Period
Time Frame: Up to 28 days
|
Up to 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 1 - Area Under Curve (AUC) of GSK4364973 (Metabolite of GSK4524101)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 1 -Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 1 - Time to Maximum Concentration of GSK4364973 (Metabolite of GSK4524101)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 1 - Half-life of GSK4364973 (Metabolite of GSK4524101) (Days)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 1 -Plasma Concentration of Niraparib
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 1 - Number of Participants with TEAEs and SAEs based on Severity beyond DLT Observation Period
Time Frame: Up to approximately 24 weeks
|
Up to approximately 24 weeks
|
|
|
Part 1 - Duration of TEAEs and SAEs (Days) beyond DLT Observation Period
Time Frame: Up to approximately 24 weeks
|
Up to approximately 24 weeks
|
|
|
Part 2 - Number of Participants with TEAEs and SAEs based on Severity
Time Frame: Up to approximately 52 weeks
|
Up to approximately 52 weeks
|
|
|
Part 2 - Duration of Treatment Emergent AEs and SAEs (Days)
Time Frame: Up to approximately 52 weeks
|
Up to approximately 52 weeks
|
|
|
Part 2 - Progression-free Survival (PFS)
Time Frame: Up to approximately 52 weeks
|
PFS is time from randomization to progressive disease or death from any cause, whichever is earlier, as assessed via RECIST v1.1 by Investigator assessment
|
Up to approximately 52 weeks
|
|
Part 2 - Duration of Response (DOR)
Time Frame: Up to approximately 52 weeks
|
DOR is defined as time from first documented PR or better to disease progression (as assessed by RECIST v1.1 by investigator assessment) or death whichever is earlier for participants who have achieved a CR or PR
|
Up to approximately 52 weeks
|
|
Part 2 -Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 2 - Minimum Concentration (Cmin) of GSK4364973 (Metabolite of GSK4524101)
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
|
|
Part 2 -Plasma Concentration of Niraparib
Time Frame: Up to 21 weeks
|
Up to 21 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 219590
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.